Top
Main

All outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Tixagevimab/cilgavimab  COVID-19 treatment studies for Tixagev../c..  C19 studies: Tixagev../c..  Tixagev../c..   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Tixagevimab/cilgavimab for COVID-19: real-time meta analysis of 6 studies
Covid Analysis, September 30, 2022, DRAFT
https://c19early.com/tcmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Montgom.. (DB RCT) 0% 1.00 [0.32-3.07] death 6/452 6/451 Improvement, RR [CI] Treatment Control Montgom.. (DB RCT) 50% 0.50 [0.29-0.86] severe case 18/407 37/415 Montgom.. (DB RCT) 57% 0.43 [0.25-0.75] hosp. 17/413 40/421 Holland (DB RCT) 30% 0.70 [0.50-0.97] death 61/710 86/707 Holland (DB RCT) 7% 0.93 [0.83-1.03] no recov. 710 (n) 707 (n) FDA (DB RCT) 40% 0.60 [0.35-1.03] symp. case 28/749 23/372 FDA (DB RCT) 33% 0.67 [0.36-1.24] symp. case 23/749 17/372 Levin (DB RCT) 86% 0.14 [0.01-2.98] death 0/3,441 2/1,731 Levin (DB RCT) 82% 0.18 [0.09-0.35] symp. case 11/3,441 31/1,731 Levin (DB RCT) 76% 0.24 [0.10-0.55] symp. case 8/3,441 17/1,731 Young-Xu (PSM) 64% 0.36 [0.18-0.73] death 1,733 (n) 6,354 (n) Immunocompromised Young-Xu (PSM) 69% 0.31 [0.18-0.53] cases/death/hosp. 17/1,733 206/6,354 Immunocompromised Young-Xu (PSM) 87% 0.13 [0.02-0.99] hosp. 1,733 (n) 6,354 (n) Immunocompromised Young-Xu (PSM) 66% 0.34 [0.13-0.87] cases 1,733 (n) 6,354 (n) Immunocompromised Kertes 92% 0.08 [0.01-0.54] death/hosp. 1/825 63/4,299 Immunocompromised Kertes 47% 0.53 [0.32-0.85] cases 29/825 308/4,299 Immunocompromised tixagevimab/cilgavimab COVID-19 outcomes c19early.com/tc Sep 2022 Favors tixagevimab/ci.. Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit